MARKET

TARS

TARS

Tarsus Pharmaceuticals, Inc.
NASDAQ
67.23
+0.98
+1.48%
Opening 14:10 03/30 EDT
OPEN
66.08
PREV CLOSE
66.25
HIGH
67.68
LOW
64.57
VOLUME
195.88K
TURNOVER
--
52 WEEK HIGH
85.25
52 WEEK LOW
38.51
MARKET CAP
2.86B
P/E (TTM)
-42.2937
1D
5D
1M
3M
1Y
5Y
1D
Barclays Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)
TipRanks · 11h ago
How China TP-03 Approval and US$15 Million Milestone Could Shape Tarsus Pharmaceuticals (TARS) Investors
Simply Wall St · 17h ago
Analysts’ Top Healthcare Picks: Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA)
TipRanks · 2d ago
Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho
TipRanks · 4d ago
Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS)
TipRanks · 5d ago
Tarsus COO Neervannan Seshadri disposes of USD 199,516 in common shares
Reuters · 5d ago
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade
The Motley Fool · 6d ago
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Climb Bio (CLYM) and Boston Scientific (BSX)
TipRanks · 6d ago
More
About TARS
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Webull offers Tarsus Pharmaceuticals Inc stock information, including NASDAQ: TARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARS stock methods without spending real money on the virtual paper trading platform.